On the last trading day, the Dow Jones Industrial Average declined 0.00%. The Nasdaq Composite Index rose 0.73% and the S&P Index fell 0.30%.
On Wednesday, there was two traditional IPO filed, while three new stock officially listed for trading.
Russian online real estate classifieds platform Cian, founded in 2001, is one of the country’s largest real estate database platform.
According to Reuters, Cian has hired underwritters including Morgan Stanley, Goldman Sachs, JPMorgan, UBS to arrange the deal, which may come with a dual listing in Moscow.
One of the sources said the offering could be around $300 million.
UserTesting, founded in 2017, provides an enterprise-grade SaaS platform for usability testing.
The company states that it has pioneered a video-first, enterprise-grade SaaS platform that enables organizations to see and hear the experiences of real people as they engage with products, designs, apps, processes, concepts, or brands.
Payment platform AvidXchange provides payment solutions for middle market businesses and their suppliers.
The company makes software that automates payments, invoicing and accounting for small- and mid-sized businesses. It says its platform allows to process invoices faster than paper-intensive methods.
The company leaped to a roughly $2 billion valuation with its latest round of fundraising. According to a statement from AvidXchange, the $260 million round was led by TPG Sixth Street Partners, andAvidXchange already counted venture capitalist Peter Thiel and payments network Mastercard Inc. among its backers.
Related：
IPO-pedia | Mastercard-backed AvidXchange seeks valuation of nearly $5 bln in IPO
https://news.moomoo.com/post/6168702
Catalyst Bancorp operates as a bank holding company for St. Landry Homestead Federal Savings Bank. The Company offers saving accounts, account checking, consumer and business loans, credit and debit cards, online and mobile banking, bill payment, and other financial services.
Genetic medicines company Verve Therapeutics, founded in 2018, pioneers a new approach to the care of cardiovascular disease, or CVD, transforming treatment from chronic management to single-course gene editing medicines.
Its initial two programs target PCSK9 and ANGPTL3, respectively, genes that have been extensively validated as targets for lowering blood lipids.
It is advancing a pipeline of single-course in vivo gene editing programs, each designed to mimic natural disease resistance mutations and turn off specific genes in order to lower blood lipids, thereby reducing the risk of ASCVD.
It went public in June 16th, 2021 and surged 68% in its market debut. As if October 13th, it has a market cap of $2.07 billion, with a listed-to-date return of 126.58%.
$Verve Therapeutics(VERV.US)$$AvidXchange(AVDX.US)$$Healthcare Triangle(HCTI.US)$$Catalyst Bancorp(CLST.US)$